Searched for: in-biosketch:true
person:gondat01
New onset diabetes predicts progression of low risk pancreatic mucinous cysts
Schweber, Adam B; Brooks, Christian; Agarunov, Emil; Sethi, Amrita; Poneros, John M; Schrope, Beth A; Kluger, Michael D; Chabot, John A; Gonda, Tamas A
BACKGROUND:Patients with low-risk lesions require ongoing surveillance since the rate of progression to pancreatic cancer (PC), while small, is much greater than in the general population. Our objective was to study the relationship between new onset diabetes (NODM) and progression in patients with low risk mucinous cysts. METHODS:We evaluated a prospectively maintained cohort of 442 patients with a suspected mucinous cyst without worrisome features (WF) or high-risk stigmata (HRS). Multivariable Cox models were developed for progression to WF and HRS, with diabetes status formulated as both time independent and dependent covariates. The adjusted cumulative risk of progression was calculated using the corrected group prognosis method. RESULTS:The 5-year cumulative progression rates to WFs and HRS were 12.8 and 3.6%, respectively. After controlling for other risk factors, the development of NODM was strongly associated with progression to HRS (HRÂ =Â 11.6; 95%CI, 3.5-57.7%), but not WF. Among patients with the smallest cysts (<10Â mm) at baseline, those who developed NODM had a 5-year adjusted cumulative risk of progression to HRS of 8.6% (95%CI, 0.0%-20.2%), compared to only 0.8% (95%CI, 0.0%-2.3%) for patients without NODM. Among patients with the largest cysts (20-29Â mm), those who developed NODM during surveillance had a 5-year adjusted cumulative risk of progression of 53.5% (95%CI, 19.6%-89.9%) compared to only 7.5% (95%CI, 1.6%-15.2%) for patients without NODM. CONCLUSION/CONCLUSIONS:New onset diabetes may predict progression in patients with low risk mucinous cysts. Pending validation with large-scale studies, these findings support regular diabetes screening among patients surveilled for suspected IPMNs or MCNs.
PMID: 33250091
ISSN: 1424-3911
CID: 4693792
Gastrointestinal endoscopy during the coronavirus pandemic in the New York area: results from a multi-institutional survey
Mahadev, Srihari; Aroniadis, Olga C; Barraza, Luis H; Agarunov, Emil; Smith, Michael S; Goodman, Adam J; Benias, Petros C; Buscaglia, Jonathan M; Gross, Seth A; Kasmin, Franklin; Cohen, Jonathan; Carr-Locke, David L; Greenwald, David; Mendelsohn, Robin; Sethi, Amrita; Gonda, Tamas A
Background and study aims  The coronavirus disease 2019 (COVID-19), and measures taken to mitigate its impact, have profoundly affected the clinical care of gastroenterology patients and the work of endoscopy units. We aimed to describe the clinical care delivered by gastroenterologists and the type of procedures performed during the early to peak period of the pandemic. Methods  Endoscopy leaders in the New York region were invited to participate in an electronic survey describing operations and clinical service. Surveys were distributed on April 7, 2020 and responses were collected over the following week. A follow-up survey was distributed on April 20, 2020. Participants were asked to report procedure volumes and patient characteristics, as well protocols for staffing and testing for COVID-19. Results  Eleven large academic endoscopy units in the New York City region responded to the survey, representing every major hospital system. COVID patients occupied an average of 54.5 % (18 - 84 %) of hospital beds at the time of survey completion, with 14.5 % (2 %-23 %) of COVID patients requiring intensive care. Endoscopy procedure volume and the number of physicians performing procedures declined by 90 % (66 %-98 %) and 84.5 % (50 %-97 %) respectively following introduction of restricted practice. During this period the most common procedures were EGDs (7.9/unit/week; 88 % for bleeding; the remainder for foreign body and feeding tube placement); ERCPs (5/unit/week; for cholangitis in 67 % and obstructive jaundice in 20 %); Colonoscopies (4/unit/week for bleeding in 77 % or colitis in 23 %) and least common were EUS (3/unit/week for tumor biopsies). Of the sites, 44 % performed pre-procedure COVID testing and the proportion of COVID-positive patients undergoing procedures was 4.6 % in the first 2 weeks and up to 19.6 % in the subsequent 2 weeks. The majority of COVID-positive patients undergoing procedures underwent EGD (30.6 % COVID +) and ERCP (10.2 % COVID +). Conclusions  COVID-19 has profoundly impacted the operation of endoscopy units in the New York region. Our data show the impact of a restricted emergency practice on endoscopy volumes and the proportion of expected COVID positive cases during the peak time of the pandemic.
PMCID:7695511
PMID: 33269322
ISSN: 2364-3722
CID: 4694312
Immediate and durable therapeutic response after EUS-guided radiofrequency ablation of a pancreatic insulinoma
Brown, Nicholas G; Patel, Anish A; Gonda, Tamas A
PMCID:7730508
PMID: 33319140
ISSN: 2468-4481
CID: 4717732
A DNA hypomethylating drug alters the tumor microenvironment and improves the effectiveness of immune checkpoint inhibitors in a mouse model of pancreatic cancer
Gonda, Tamas A; Fang, Jarwei; Salas, Martha; Do, Catherine; Hsu, Emily; Zhukovskaya, Anna; Siegel, Ariel; Takahashi, Ryota; Lopez-Bujanda, Zoila A; Drake, Charles G; Manji, Gulam Abbas; Wang, Timothy C; Olive, Kenneth P; Tycko, Benjamin
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer that has proven refractory to immunotherapy. Previously, treatment with the DNA hypomethylating drug decitabine (5aza-dC; DAC) extended survival in the KPC-Brca1 mouse model of PDAC. Here we investigated the effects of DAC in the original KPC model and tested combination therapy with DAC followed by immune checkpoint inhibitors (ICI). Four protocols were tested: PBS vehicle, DAC, ICI (anti-PD-1 or anti-VISTA), and DAC followed by ICI. For each single-agent and combination treatment, tumor growth was measured by serial ultrasound, tumor infiltrating lymphoid and myeloid cells were characterized, and overall survival was assessed. Single-agent DAC led to increased CD4+ and CD8+ tumor-infiltrating T cells (TILs), PD1 expression, and tumor necrosis while slowing tumor growth and modestly increasing mouse survival without systemic toxicity. RNA-seq of DAC-treated tumors revealed increased expression of Chi3l3 (Ym1), reflecting an increase in a subset of tumor-infiltrating M2-polarized macrophages. While ICI alone had modest effects, DAC followed by either of ICI therapy additively inhibited tumor growth and prolonged mouse survival. The best results were obtained using DAC followed by anti-PD-1, which extended mean survival from 26 to 54 days (p<0.0001). In summary, low-dose DAC inhibits tumor growth and increases both TIL and a subset of tumor-infiltrating M2-polarized macrophages in the KPC model of PDAC, and DAC followed by anti-PD-1 substantially prolongs survival. Since M2-polarized macrophages are predicted to antagonize anti-tumor effects, targeting these cells may be important to enhance the efficacy of combination therapy with DAC plus ICI.
PMID: 32816859
ISSN: 1538-7445
CID: 4567162
Impact of the COVID-19 pandemic on endoscopy practice: results of a cross-sectional survey from the New York metropolitan area [Letter]
Mahadev, SriHari; Aroniadis, Olga S; Barraza, Luis; Agarunov, Emil; Goodman, Adam J; Benias, Petros C; Buscaglia, Jonathan M; Gross, Seth A; Kasmin, Franklin E; Cohen, Jonathan J; Carr-Locke, David L; Greenwald, David A; Mendelsohn, Robin B; Sethi, Amrita; Gonda, Tamas A
PMCID:7182511
PMID: 32339595
ISSN: 1097-6779
CID: 4438472
Helicobacter pylori antibiotic eradication coupled with a chemically defined diet in INS-GAS mice triggers dysbiosis and vitamin K deficiency resulting in gastric hemorrhage
Quinn, Lisa; Sheh, Alexander; Ellis, Jessie L; Smith, Donald E; Booth, Sarah L; Fu, Xueyan; Muthupalani, Sureshkumar; Ge, Zhongming; Puglisi, Dylan A; Wang, Timothy C; Gonda, Tamas A; Holcombe, Hilda; Fox, James G
Infection with Helicobacter pylori causes chronic inflammation and is a risk factor for gastric cancer. Antibiotic treatment or increased dietary folate prevents gastric carcinogenesis in male INS-GAS mice. To determine potential synergistic effects, H. pylori-infected male INS-GAS mice were fed an amino acid defined (AAD) diet with increased folate and were treated with antibiotics after 18 weeks of H. pylori infection. Antibiotic therapy decreased gastric pathology, but dietary folate had no effect. However, the combination of antibiotics and the AAD diet induced anemia, gastric hemorrhage, and mortality. Clinical presentation suggested hypovitaminosis K potentially caused by dietary deficiency and dysbiosis. Based on current dietary guidelines, the AAD diet was deficient in vitamin K. Phylloquinone administered subcutaneously and via a reformulated diet led to clinical improvement with no subsequent mortalities and increased hepatic vitamin K levels. We characterized the microbiome and menaquinone profiles of antibiotic-treated and antibiotic-free mice. Antibiotic treatment decreased the abundance of menaquinone producers within orders Bacteroidales and Verrucomicrobiales. PICRUSt predicted decreases in canonical menaquinone biosynthesis genes, menA and menD. Reduction of menA from Akkermansia muciniphila, Bacteroides uniformis, and Muribaculum intestinale were confirmed in antibiotic-treated mice. The fecal menaquinone profile of antibiotic-treated mice had reduced MK5 and MK6 and increased MK7 and MK11 compared to antibiotic-free mice. Loss of menaquinone-producing microbes due to antibiotics altered the enteric production of vitamin K. This study highlights the role of diet and the microbiome in maintaining vitamin K homeostasis.
PMID: 31955643
ISSN: 1949-0984
CID: 4520962
Donning a new approach to the practice of gastroenterology: perspectives from the COVID-19 pandemic epicenter
Sethi, Amrita; Swaminath, Arun; Latorre, Melissa; Behin, Daniel S; Jodorkovsky, Daniela; Calo, Delia; Aroniadis, Olga; Mone, Anjali; Mendelsohn, Robin B; Sharaiha, Reem Z; Gonda, Tamas A; Khanna, Lauren G; Bucobo, Juan Carlos; Nagula, Satish; Ho, Sammy; Carr-Locke, David L; Robbins, David H
The COVID-19 pandemic is seemingly peaking now in New York City and has triggered significant changes to the standard management of gastrointestinal diseases. Priorities such as minimizing viral transmission, preserving (personal protective equipment) PPE, and freeing hospital beds have driven unconventional approaches to managing GI patients. Conversion of endoscopy units to COVID units and redeployment of gastroenterology (GI) fellows and faculty has profoundly changed the profile of most GI services. Meanwhile, consult and procedural volumes have been drastically reduced. In this review we share our collective experiences, how we have changed our practice of medicine, in response to the COVID surge. While we will review our management of specific consults and conditions, the overarching theme focuses primarily on non-invasive measures and maximizing medical therapies. Endoscopic procedures have been reserved for those timely interventions that are most likely to be therapeutic. The role of multidisciplinary discussion, while always important, has now become critical. And the support of our faculty and trainees remains essential. Local leadership can encourage well-being by frequent team check-ins and foster trainee development through remote learning. Advancing a clear vision and a transparent process for how to organize and triage care in the recovery phase will allow for a smooth transition to our "new normal."
PMID: 32330565
ISSN: 1542-7714
CID: 4397502
Outcomes of Hemospray therapy in the treatment of intraprocedural upper gastrointestinal bleeding post-endoscopic therapy
Hussein, Mohamed; Alzoubaidi, Durayd; Serna, Alvaro de la; Weaver, Michael; Fernandez-Sordo, Jacobo O; Rey, Johannes W; Hayee, Bu'Hussain; Despott, Edward; Murino, Alberto; Moreea, Sulleman; Boger, Phil; Dunn, Jason; Mainie, Inder; Graham, David; Mullady, Dan; Early, Dayna; Ragunath, Krish; Anderson, John; Bhandari, Pradeep; Goetz, Martin; Kiesslich, Ralf; Coron, Emmanuel; de Santiago, Enrique R; Gonda, Tamas; Lovat, Laurence B; Haidry, Rehan
INTRODUCTION/BACKGROUND:With increasing advances in minimally invasive endoscopic therapies and endoscopic resection techniques for luminal disease, there is an increased risk of post-procedure bleeding. This can contribute to significant burden on patient's quality of life and health resources when reintervention is required. Hemospray (Cook Medical, North Carolina, USA) is a novel haemostatic powder licensed for gastrointestinal bleeding. The aim of this single-arm, prospective, non-randomised multicentre international study is to look at outcomes in patients with upper gastrointestinal bleeds following elective endoscopic therapy treated with Hemospray to achieve haemostasis. METHODS:Data was prospectively collected on the use of Hemospray from 16 centres (January 2016-November 2019). Hemospray was used during the presence of progressive intraprocedural bleeding post-endoscopic therapy as a monotherapy, dual therapy with standard haemostatic techniques or rescue therapy once standard methods had failed. Haemostasis was defined as the cessation of bleeding within 5 min of the application of Hemospray. Re-bleeding was defined as a sustained drop in haemoglobin (>2 g/l), haematemesis or melaena with haemodynamic instability after the index endoscopy. RESULTS:A total of 73 patients were analysed with bleeding post-endoscopic therapy. The median Blatchford score at baseline was five (interquartile range 0-9). The median Rockall score was six (interquartile range 5-7). Immediate haemostasis following the application of Hemospray was achieved in 73/73 (100%) of patients. Two out of 57 (4%) had a re-bleed post-Hemospray, one was following oesophageal endoscopic mucosal resection and the other post-duodenal endoscopic mucosal resection. Both patients had a repeat endoscopy and therapy within 24 h. Re-bleeding data was missing for 16 patients, and mortality data was missing for 14 patients. There were no adverse events recorded in association with the use of Hemospray. CONCLUSION/CONCLUSIONS:Hemospray is safe and effective in achieving immediate haemostasis following uncontrolled and progressive intraprocedural blood loss post-endoscopic therapy, with a low re-bleed rate.
PMID: 32588788
ISSN: 2050-6414
CID: 4520982
Endoscopic Algorithm for Management of Gastrointestinal Bleeding in Patients with CF-LVADs: A Prospective Validation Study
Axelrad, Jordan E; Faye, Adam S; Pinsino, Alberto; Thanataveerat, Anusorn; Cagliostro, Barbara; Pineda, Marie Finelle T; Ross, Katherine; Te-Frey, Rosie T; Effner, Lisa; Garan, Arthur R; Topkara, Veli K; Takayama, Hiroo; Takeda, Koji; Naka, Yoshifumi; Ramirez, Ivonne; Garcia-Carrasquillo, Reuben; Colombo, Paolo C; Gonda, Tamas; Yuzefpolskaya, Melana
BACKGROUND:GIBÂ is a common complication of LVAD therapy accounting for frequent hospitalizations and high resource utilization. METHODS:We previously developed an endoscopic algorithm emphasizing upfront evaluation of the small bowel and minimizing low-yield procedures in LVAD recipients with GIB. We compared the diagnostic and therapeutic yield of endoscopy, healthcare costs, and re-bleeding rates between conventional GIB management and our algorithm using chi-square, Fisher's exact test, Wilcoxon-Mann-Whitney, and Kaplan-Meier analysis. RESULTS:We identified 33 LVAD patients with GIB. Presentation was consistent with upper GIB in 20 (61%), lower GIB in 5 (15%), and occult GIB in 8 (24%) patients. 41 endoscopies localized a source in 23 (56%), resulting in 14 (34%) interventions. Algorithm implementation in comparison to our conventional cohort was associated with a 68% increase in endoscopic diagnostic yield (p<0.01), a 113% increase in therapeutic yield (p=0.01), a 27 % reduction in the number of procedures per patient (p<0.01), a 33% decrease in length of stay (p<0.01), and an 18% reduction in estimated costs (p<0.01). The same median number of red blood cell transfusions were used in the two cohorts, with no increase in re-bleeding events in the algorithm cohort (33.3%) as compared to our conventional cohort (43.7%). CONCLUSIONS:Our endoscopic management algorithm for GIB in LVAD patients proved effective in reducing low-yield procedures, improving the diagnostic and therapeutic yield of endoscopy, decreasing healthcare resource utilization and costs, while not increasing the risk of a re-bleeding event.
PMID: 31794863
ISSN: 1532-8414
CID: 4218392
The Role of Endoscopic Ultrasound-Guided Ki67 in The Management of Non-Functioning Pancreatic Neuroendocrine Tumors
Cui, YongYan; Khanna, Lauren G; Saqi, Anjali; Crapanzano, John P; Mitchell, James M; Sethi, Amrita; Gonda, Tamas A; Kluger, Michael D; Schrope, Beth A; Allendorf, John; Chabot, John A; Poneros, John M
Background/Aims/UNASSIGNED:The management of small, incidentally discovered nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) has been a matter of debate. Endoscopic ultrasound with fine-needle aspiration (EUS-FNA) is a tool used to identify and risk-stratify PNETs. This study investigates the concordance rate of Ki67 grading between EUS-FNA and surgical pathology specimens in NFPNETs and whether certain NF-PNET characteristics are associated with disease recurrence and disease-related death. Methods/UNASSIGNED:: We retrospectively reviewed the clinical history, imaging, endoscopic findings, and pathology records of 37 cases of NFPNETs that underwent pre-operative EUS-FNA and surgical resection at a single academic medical center. Results/UNASSIGNED:: There was 73% concordance between Ki67 obtained from EUS-FNA cytology and surgical pathology specimens; concordance was the highest for low- and high-grade NF-PNETs. High-grade Ki67 NF-PNETs based on cytology (p=0.028) and histology (p=0.028) were associated with disease recurrence and disease-related death. Additionally, tumors with high-grade mitotic rate (p=0.005), tumor size >22.5 mm (p=0.104), and lymphovascular invasion (p=0.103) were more likely to have poor prognosis. Conclusions/UNASSIGNED:: NF-PNETs with high-grade Ki67 on EUS-FNA have poor prognosis despite surgical resection. NF-PNETs with intermediate-grade Ki67 on EUS-FNA should be strongly considered for surgical resection. NF-PNETs with low-grade Ki67 on EUSFNA can be monitored without surgical intervention, up to tumor size 20 mm.
PMID: 31302988
ISSN: 2234-2400
CID: 4014882